Header Logo

Connection

JORGE CASTILLO to Prognosis

Back to Details
This is a "connection" page, showing publications JORGE CASTILLO has written about Prognosis.
JORGE CASTILLO
Connection Strength
3.081
Prognosis
  1. Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy. Cancer Rep (Hoboken). 2024 Sep; 7(9):e2126.
    View in: PubMed
    Score: 0.120
  2. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol. 2024 Oct; 99(10):2002-2015.
    View in: PubMed
    Score: 0.118
  3. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
    View in: PubMed
    Score: 0.117
  4. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 02; 98(2):300-308.
    View in: PubMed
    Score: 0.107
  5. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022 07; 97(7):951-965.
    View in: PubMed
    Score: 0.102
  6. Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK?+?LBCL): a systematic review of clinicopathological features and management. Leuk Lymphoma. 2021 12; 62(12):2845-2853.
    View in: PubMed
    Score: 0.096
  7. Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leuk Lymphoma. 2021 12; 62(12):2882-2889.
    View in: PubMed
    Score: 0.096
  8. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 04; 95(4):435-445.
    View in: PubMed
    Score: 0.088
  9. CXCR4 mutational status does not impact outcomes in patients with Waldenstr?m macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98.
    View in: PubMed
    Score: 0.087
  10. Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematol Oncol Clin North Am. 2019 08; 33(4):639-656.
    View in: PubMed
    Score: 0.083
  11. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 07; 93(7):953-962.
    View in: PubMed
    Score: 0.078
  12. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and?overall survival. Br J Haematol. 2018 02; 180(3):374-380.
    View in: PubMed
    Score: 0.075
  13. MYD88 mutations can be used to identify malignant pleural effusions in Waldenstr?m macroglobulinaemia. Br J Haematol. 2018 02; 180(4):578-581.
    View in: PubMed
    Score: 0.069
  14. "All the soarings of my mind begin in my blood:" central nervous system complication of Waldenstr?m macroglobulinemia. Am J Hematol. 2016 Oct; 91(10):1057-60.
    View in: PubMed
    Score: 0.068
  15. Renal disease related to Waldenstr?m macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630.
    View in: PubMed
    Score: 0.068
  16. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. Cancer. 2016 09 01; 122(17):2689-97.
    View in: PubMed
    Score: 0.068
  17. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016 May; 91(5):529-37.
    View in: PubMed
    Score: 0.067
  18. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 06; 91(6):575-80.
    View in: PubMed
    Score: 0.067
  19. Central nervous system involvement by Waldenstr?m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
    View in: PubMed
    Score: 0.065
  20. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015 Aug; 26(8):1163-72.
    View in: PubMed
    Score: 0.063
  21. The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 09; 125(15):2323-30.
    View in: PubMed
    Score: 0.062
  22. Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
    View in: PubMed
    Score: 0.061
  23. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015 Feb 01; 121(3):423-31.
    View in: PubMed
    Score: 0.060
  24. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res. 2014 Sep; 38(9):1067-71.
    View in: PubMed
    Score: 0.059
  25. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr?m's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
    View in: PubMed
    Score: 0.059
  26. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014 Mar; 89(3):310-4.
    View in: PubMed
    Score: 0.058
  27. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Oct 15; 119(20):3672-9.
    View in: PubMed
    Score: 0.055
  28. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2013 Apr; 37(4):386-91.
    View in: PubMed
    Score: 0.054
  29. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012 Dec; 53(12):2378-82.
    View in: PubMed
    Score: 0.051
  30. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012 Nov 01; 118(21):5270-7.
    View in: PubMed
    Score: 0.051
  31. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012 Apr; 36(4):413-7.
    View in: PubMed
    Score: 0.050
  32. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):185-9.
    View in: PubMed
    Score: 0.047
  33. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. Am J Hematol. 2011 Mar; 86(3):256-61.
    View in: PubMed
    Score: 0.047
  34. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011; 16(1):87-96.
    View in: PubMed
    Score: 0.046
  35. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2010 Oct; 51(10):1822-8.
    View in: PubMed
    Score: 0.046
  36. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010; 15(3):293-9.
    View in: PubMed
    Score: 0.044
  37. Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia. Am J Hematol. 2025 Jun; 100(6):980-986.
    View in: PubMed
    Score: 0.031
  38. Simplified Risk Stratification Model for Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2024 Jul 20; 42(21):2527-2536.
    View in: PubMed
    Score: 0.029
  39. The prognostic role of red cell distribution width on all-cause and cause-specific outcomes in peripheral T-cell lymphoma: a retrospective cohort study. Leuk Lymphoma. 2023 Jul-Aug; 64(7):1225-1233.
    View in: PubMed
    Score: 0.027
  40. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Oncol. 2023 03 01; 41(7):1383-1392.
    View in: PubMed
    Score: 0.026
  41. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
    View in: PubMed
    Score: 0.024
  42. Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leuk Res. 2021 03; 102:106513.
    View in: PubMed
    Score: 0.023
  43. Partial response or better at six?months is prognostic of superior progression-free survival in Waldenstr?m macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 02; 192(3):542-550.
    View in: PubMed
    Score: 0.023
  44. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr?m macroglobulinemia: the ASPEN study. Blood. 2020 10 29; 136(18):2038-2050.
    View in: PubMed
    Score: 0.023
  45. Primary refractory multiple myeloma: a real-world experience with 85 cases. Leuk Lymphoma. 2020 12; 61(12):2868-2875.
    View in: PubMed
    Score: 0.022
  46. Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. Leuk Lymphoma. 2020 09; 61(9):2093-2102.
    View in: PubMed
    Score: 0.022
  47. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):637-646.
    View in: PubMed
    Score: 0.022
  48. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leuk Lymphoma. 2020 08; 61(8):1885-1893.
    View in: PubMed
    Score: 0.022
  49. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):e551-e557.
    View in: PubMed
    Score: 0.021
  50. Progression Risk Stratification of Asymptomatic Waldenstr?m Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
    View in: PubMed
    Score: 0.021
  51. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Cancer. 2019 02 15; 125(4):550-558.
    View in: PubMed
    Score: 0.020
  52. Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. Am J Hematol. 2018 09; 93(9):E238-E241.
    View in: PubMed
    Score: 0.020
  53. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. Leuk Res. 2018 04; 67:82-85.
    View in: PubMed
    Score: 0.019
  54. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018 06; 59(6):1375-1383.
    View in: PubMed
    Score: 0.019
  55. Ibrutinib for patients with rituximab-refractory Waldenstr?m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250.
    View in: PubMed
    Score: 0.018
  56. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2016; 57(1):58-62.
    View in: PubMed
    Score: 0.016
  57. Survival outcomes of secondary cancers in patients with Waldenstr?m macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug; 90(8):696-701.
    View in: PubMed
    Score: 0.016
  58. Plasma fatty acid profile in multiple myeloma patients. Leuk Res. 2015 Apr; 39(4):400-5.
    View in: PubMed
    Score: 0.015
  59. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013 Sep; 37(9):1107-15.
    View in: PubMed
    Score: 0.014
  60. Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature. Leuk Res. 2013 Sep; 37(9):1116-9.
    View in: PubMed
    Score: 0.014
  61. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. Leuk Lymphoma. 2011 Jan; 52(1):153-6.
    View in: PubMed
    Score: 0.012
  62. Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. Leuk Res. 2011 Mar; 35(3):334-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.